264 related articles for article (PubMed ID: 9833620)
21. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
Song SQ; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
[TBL] [Abstract][Full Text] [Related]
22. [Methotrexate in gynecologic oncology].
Isonishi S; Terashima Y
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1896-900. PubMed ID: 8978793
[TBL] [Abstract][Full Text] [Related]
23. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.
Soto-Wright V; Goldstein DP; Bernstein MR; Berkowitz RS
Gynecol Oncol; 1997 Jan; 64(1):156-9. PubMed ID: 8995566
[TBL] [Abstract][Full Text] [Related]
24. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
[TBL] [Abstract][Full Text] [Related]
25. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
Byun SW; Park TC; Bae SN
Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
[TBL] [Abstract][Full Text] [Related]
26. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
Kohorn EI
Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
[TBL] [Abstract][Full Text] [Related]
27. Management of drug resistant gestational trophoblastic neoplasia.
Patel SM; Desai A
J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S
Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405
[TBL] [Abstract][Full Text] [Related]
29. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
[TBL] [Abstract][Full Text] [Related]
30. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X
Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of patients with trophoblastic tumors in the Academic Medical Center: 31 patients in 10 years, 1983-1992].
Laan R; Bakker P; Lammes FB
Ned Tijdschr Geneeskd; 1995 Sep; 139(36):1829-34. PubMed ID: 7477506
[TBL] [Abstract][Full Text] [Related]
32. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
33. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
34. [Methotrexate combined chemotherapy for chemorefractory gestational trophoblastic tumour].
Xiang Y; Yang X; Han S
Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):97-100. PubMed ID: 11263207
[TBL] [Abstract][Full Text] [Related]
35. Successful resolution of persistent trophoblastic disease after partial mole with the EMA-CO regimen.
Dgani R; Zalel Y; Biran H; Blickstein I; Caspi B; Weissman A; Shoham Z
Eur J Obstet Gynecol Reprod Biol; 1994 Mar; 54(1):77-9. PubMed ID: 7519153
[TBL] [Abstract][Full Text] [Related]
36. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities.
Matsui H; Iitsuka Y; Seki K; Sekiya S
Gynecol Obstet Invest; 1998; 46(1):5-8. PubMed ID: 9692333
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of gestational trophoblastic disease at a single institute.
Alici S; Eralp Y; Saip P; Argon A; Basaran M; Topuz E; Aydiner A
Tohoku J Exp Med; 2002 Jun; 197(2):95-100. PubMed ID: 12233789
[TBL] [Abstract][Full Text] [Related]
38. Placental site trophoblastic tumor: an overview.
Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; Cantú MG
J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy after EMA/CO for gestational trophoblastic disease: a report from The Netherlands.
Lok CA; van der Houwen C; ten Kate-Booij MJ; van Eijkeren MA; Ansink AC
BJOG; 2003 Jun; 110(6):560-6. PubMed ID: 12798472
[TBL] [Abstract][Full Text] [Related]
40. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
Curry SL; Blessing JA; DiSaia PJ; Soper JT; Twiggs LB
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):357-62. PubMed ID: 2536911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
